phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"phgenomics-153Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫCURRENT REVIEWПоловые различия как платформа для понимания фармакологического статуса женщинSex differences as a platform for understanding the pharmacological status of womenРешетькоО. В.ReshetkoO. V.

Решетько Ольга Вилоровна — д.м.н., профессор, зав. кафедрой фармакологии.

г. Саратов, 410012, ул. Большая Казачья, 112

reshetko@yandex.ruЛуцевичК. А.LutsevichK. A.ГБОУ ВПО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава РФРоссияV.I. Razumovsky Saratov State Medical UniversityRussian Federation20152403202001411Copyright © Решетько О.В., Луцевич К.А., 20202020Решетько О.В., Луцевич К.А.Reshetko O.V., Lutsevich K.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/153

Существуют многочисленные пробелы в понимании связанных с полом различий в действии лекарственных средств (ЛС). Эти различия важны, так как они потенциально оказывают влияние на эффективность фармакотерапии или на нежелательные эффекты ЛС. Установлено, что нежелательные эффекты, вызываемые ЛС, наиболее часто наблюдаются у женщин, чем у мужчин. Связанные с полом особенности обычно вовлекают различия в фармакокинетике (то есть, всасывание, распределение, метаболизм и экскрецию) или фармакодинамике (взаимоотношение между эффектом и концентрацией в месте действия) ЛС. В качестве первого шага к индивидуализированной или персонализированной медицине предлагается направить усилия на изучение половых различий, как в фундаментальной науке, так и в клинической практике.

There are still many gaps in the understanding of sex-related differences in drug action. These differences are important since they are potentially affecting the clinical effectiveness of the therapy or impacting on its side effects. It has been established that side effects produced by drugs are more frequent in women than in men. Sex-based effects usually involve differences in pharmacokinetics (i.e., the way the drug is absorbed, distributed, metabolized, and excreted) or pharmacodynamics (the relationship between drug effect and drug concentration at the site of action). Sex-based medicine could be the first step in offering individualized or personalized medicine that would consider individual differences both in basic science and in clinical practice.

половые различияфармакокинетикафармакодинамикалекарственная экспозициянежелательные лекарственные реакцииsex differencespharmacokineticspharmacodynamicsdrug dispositionadverse drug reactionsReferencesFuhr U., Jetter A., Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. // Clin Pharmacol Ther 2007; 81:270-283.Fuhr U., Jetter A., Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. // Clin Pharmacol Ther 2007; 81:270-283.Daly T.M., Dumaual C.M., Miao X., et al. Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport. // Clin Chem 2007; 53:1222-1230.Daly T.M., Dumaual C.M., Miao X., et al. Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport. // Clin Chem 2007; 53:1222-1230.Insburg G.S., Willard H.F. Genomic and personalized medicine: Foundations and applications. // Transl Res 2009; 154:277-287.Insburg G.S., Willard H.F. Genomic and personalized medicine: Foundations and applications. // Transl Res 2009; 154:277-287.Tingen C.M., Kim A.M., Wu P.H., Woodruff T.K. Sex and sensitivity: the continued need for sex-based biomedical research and implementation. // Women’s Health 2010; 6:511-516.Tingen C.M., Kim A.M., Wu P.H., Woodruff T.K. Sex and sensitivity: the continued need for sex-based biomedical research and implementation. // Women’s Health 2010; 6:511-516.Geller S.E., Adams M.G., Carnes M. Adherence to federal guidelines for reporting of sex and race/ethnicity in clinical trials. // J Women’s Health 2006; 15:1123-1131.Geller S.E., Adams M.G., Carnes M. Adherence to federal guidelines for reporting of sex and race/ethnicity in clinical trials. // J Women’s Health 2006; 15:1123-1131.Mattison D.R. Pharmacokinetics in real life: sex and gender differences. // Popul Ther Clin Pharmacol 2013; 20:e340-e349.Mattison D.R. Pharmacokinetics in real life: sex and gender differences. // Popul Ther Clin Pharmacol 2013; 20:e340-e349.Nicolas J.M., Espie P., Molimard M. Gender and interindividual variability in pharmacokinetics. // Drug Metab Rev 2009; 41:408-421.Nicolas J.M., Espie P., Molimard M. Gender and interindividual variability in pharmacokinetics. // Drug Metab Rev 2009; 41:408-421.Huang S.M., Temple R. Is this the drug or dose for you?: Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. // Clin Pharmacol Ther 2008; 84:287-294.Huang S.M., Temple R. Is this the drug or dose for you?: Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. // Clin Pharmacol Ther 2008; 84:287-294.Bren L. Does sex make a difference? // FDA Consum Mag 2005; 39:10-15.Bren L. Does sex make a difference? // FDA Consum Mag 2005; 39:10-15.Uhl K., Parekh A., Kweder S. Females in clinical studies: where are we going? // Clin Pharmacol Ther 2007; 81:600-602.Uhl K., Parekh A., Kweder S. Females in clinical studies: where are we going? // Clin Pharmacol Ther 2007; 81:600-602.Federman D.D. The biology of human sex differences. // N Engl J Med 2006; 354:1507-1514.Federman D.D. The biology of human sex differences. // N Engl J Med 2006; 354:1507-1514.Gray J. Why can’t a woman be more like a man? // Clin Pharmacol Ther 2007; 82:15-17.Gray J. Why can’t a woman be more like a man? // Clin Pharmacol Ther 2007; 82:15-17.Mattison Faye A.C., Mattison D.R. Sex differences in drug development. // Blickpunkt DER MANN 2008; 6:21-25.Mattison Faye A.C., Mattison D.R. Sex differences in drug development. // Blickpunkt DER MANN 2008; 6:21-25.Anderson G.D. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. // J Women’s Health 2005; 14:19-29.Anderson G.D. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. // J Women’s Health 2005; 14:19-29.Mode A., Gustafsson J.A. Sex and the liver — a journey through five decades. // Drug Metab Rev 2006; 38:197-207.Mode A., Gustafsson J.A. Sex and the liver — a journey through five decades. // Drug Metab Rev 2006; 38:197-207.Schwartz J.B. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. // Clin Pharmacol Ther 2007; 82:87-96.Schwartz J.B. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. // Clin Pharmacol Ther 2007; 82:87-96.Soldin O.P., Chung S.H., Mattison D.R. Sex differences in drug disposition. // J Biomed Biotechnol 2011; 2011:187103.Soldin O.P., Chung S.H., Mattison D.R. Sex differences in drug disposition. // J Biomed Biotechnol 2011; 2011:187103.Parekh A., Fadiran E., Uhl K., Throckmorton D. Adverse effects in women: implications for drug development and regulatory policies. // Expert Rev Clin Pharmacol 2011; 4:453-466.Parekh A., Fadiran E., Uhl K., Throckmorton D. Adverse effects in women: implications for drug development and regulatory policies. // Expert Rev Clin Pharmacol 2011; 4:453-466.Moore T.J., Cohen M.R., Furberg C.D. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. // Arch Intern Med 2007; 167:1752-1759.Moore T.J., Cohen M.R., Furberg C.D. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. // Arch Intern Med 2007; 167:1752-1759.Kando J.C., Yonkers K.A., Cole J.O. Gender as a risk factor for adverse events to medications. // Drugs 1995; 50:1-6.Kando J.C., Yonkers K.A., Cole J.O. Gender as a risk factor for adverse events to medications. // Drugs 1995; 50:1-6.Tran C., Knowles S.R., Liu B.A., Shear N.H. Gender differences in adverse drug reactions. // J Clin Pharmacol 1998; 38:1003-1009.Tran C., Knowles S.R., Liu B.A., Shear N.H. Gender differences in adverse drug reactions. // J Clin Pharmacol 1998; 38:1003-1009.Zopf Y., Rabe C., Neubert A., et al. Women encounter ADRs more often than do men. // Eur J Clin Pharmacol 2008; 64:999-1004.Zopf Y., Rabe C., Neubert A., et al. Women encounter ADRs more often than do men. // Eur J Clin Pharmacol 2008; 64:999-1004.Evans R.S., Lloyd J.F., Stoddard G.J., et al. Risk factors for adverse drug events: a 10-year analysis. // Ann Pharmacother 2005; 39:1161-1168.Evans R.S., Lloyd J.F., Stoddard G.J., et al. Risk factors for adverse drug events: a 10-year analysis. // Ann Pharmacother 2005; 39:1161-1168.Zopf Y., Rabe C., Neubert A., et al. Gender-based differences in drug prescription: relation to adverse drug reactions. // Pharmacology 2009; 84:333-339.Zopf Y., Rabe C., Neubert A., et al. Gender-based differences in drug prescription: relation to adverse drug reactions. // Pharmacology 2009; 84:333-339.Coker S.J. Drugs for men and women — how important is gender as a risk factor for TdP? // Pharmacol Ther 2008; 119:186-194.Coker S.J. Drugs for men and women — how important is gender as a risk factor for TdP? // Pharmacol Ther 2008; 119:186-194.Chu T. Gender differences in pharmacokinetics. // US Pharm 2014; 39(9):40-43.Chu T. Gender differences in pharmacokinetics. // US Pharm 2014; 39(9):40-43.Verster J.C., Roth T. Gender differences in highway driving performance after administration of sleep medication: a review of the literature. // Traffic Inj Prev 2012; 13:286-292.Verster J.C., Roth T. Gender differences in highway driving performance after administration of sleep medication: a review of the literature. // Traffic Inj Prev 2012; 13:286-292.Anthony M., Berg M.J. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I. // J Women’s Health Gend Based Med 2002; 11:601-615.Anthony M., Berg M.J. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I. // J Women’s Health Gend Based Med 2002; 11:601-615.Anthony M., Berg M.J. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics and pharmacogenetics: Part II — workshop held at the National Institutes of Health, May 4—6, 1999. // J Women’s Health Gend Based Med 2002; 11:617-629.Anthony M., Berg M.J. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics and pharmacogenetics: Part II — workshop held at the National Institutes of Health, May 4—6, 1999. // J Women’s Health Gend Based Med 2002; 11:617-629.Drici M.D., Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. // Drug Saf 2001; 24:575-585.Drici M.D., Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. // Drug Saf 2001; 24:575-585.Zhang L., Strong J.M., Qiu W., et al. Scientific perspectives on drug transporters and their role in drug interactions. // Mol Pharmacol 2006; 3:62-69.Zhang L., Strong J.M., Qiu W., et al. Scientific perspectives on drug transporters and their role in drug interactions. // Mol Pharmacol 2006; 3:62-69.Kim R.B., Zamek-Gliszczynski M.J., Hoffmaster K.A., et al. Transporters and drug discovery: why, when, and how. // Mol Pharmacol 2006; 3:26-32.Kim R.B., Zamek-Gliszczynski M.J., Hoffmaster K.A., et al. Transporters and drug discovery: why, when, and how. // Mol Pharmacol 2006; 3:26-32.Ciccone G.K., Holdcroft A. Drugs and sex differences: a review of drugs relating to anaesthesia. // Br J Anaesth 1999; 82:255-265.Ciccone G.K., Holdcroft A. Drugs and sex differences: a review of drugs relating to anaesthesia. // Br J Anaesth 1999; 82:255-265.Frezza M., di Padova C., Pozzato G., et al. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and fi rst-pass metabolism. // N Engl J Med 1990; 322:95-99.Frezza M., di Padova C., Pozzato G., et al. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and fi rst-pass metabolism. // N Engl J Med 1990; 322:95-99.Parlesak A., Billinger M.H.U., Bode C., Bode J.C. Gastric alcohol dehydrogenase activity in man: influence of gender, age, alcohol consumption and smoking in a Caucasian population. // Alcohol Alcoholism 2002; 37:388-393.Parlesak A., Billinger M.H.U., Bode C., Bode J.C. Gastric alcohol dehydrogenase activity in man: influence of gender, age, alcohol consumption and smoking in a Caucasian population. // Alcohol Alcoholism 2002; 37:388-393.Carrasco-Portugal M.C., Flores-Murrieta F.J. Gender differences in the pharmacokinetics of oral drugs. // Pharmacol Pharm 2011; 2:31-41.Carrasco-Portugal M.C., Flores-Murrieta F.J. Gender differences in the pharmacokinetics of oral drugs. // Pharmacol Pharm 2011; 2:31-41.Whitley H.P., Lindsey W. Sex-based differences in drug activity. // Am Fam Physician 2009; 80:1254-1258.Whitley H.P., Lindsey W. Sex-based differences in drug activity. // Am Fam Physician 2009; 80:1254-1258.Martinez M.N., Amidon G.L. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. // J Clin Pharmacol 2002; 42:620-643.Martinez M.N., Amidon G.L. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. // J Clin Pharmacol 2002; 42:620-643.Aichhorn W., Gasser M., Weiss E.M., et al. Gender differences in pharmacokinetics and side effects of second generation antipsychotic drugs. // Curr Neuropharmacol 2005; 3:73-85.Aichhorn W., Gasser M., Weiss E.M., et al. Gender differences in pharmacokinetics and side effects of second generation antipsychotic drugs. // Curr Neuropharmacol 2005; 3:73-85.Gandhi M., Aweeka F., Greenblatt R.M., Blaschke T.F. Sex differences in pharmacokinetics and pharmacodynamics. // Annu Rev Pharmacol Toxicol 2004; 44:499-523.Gandhi M., Aweeka F., Greenblatt R.M., Blaschke T.F. Sex differences in pharmacokinetics and pharmacodynamics. // Annu Rev Pharmacol Toxicol 2004; 44:499-523.Donovan M.D. Sex and racial differences in pharmacological response: Effect of route of administration and drug delivery system on pharmacokinetics. // J Women’s Health 2005; 14:30-37.Donovan M.D. Sex and racial differences in pharmacological response: Effect of route of administration and drug delivery system on pharmacokinetics. // J Women’s Health 2005; 14:30-37.Fletcher C.V., Acosta E.P., Strykowski J.M. Gender differences in human pharmacokinetics and pharmacodynamics. // J Adolesc Health 1994; 15:619-629.Fletcher C.V., Acosta E.P., Strykowski J.M. Gender differences in human pharmacokinetics and pharmacodynamics. // J Adolesc Health 1994; 15:619-629.Schwartz J.B. The influence of sex on pharmacokinetics. // Clin Pharmacokinet 2003; 42:107-121.Schwartz J.B. The influence of sex on pharmacokinetics. // Clin Pharmacokinet 2003; 42:107-121.Giacomini K.M., Huang S.M., Tweedie D.J., et al. Membrane transporters in drug development. // Nat Rev Drug Discov 2010; 9:215-236.Giacomini K.M., Huang S.M., Tweedie D.J., et al. Membrane transporters in drug development. // Nat Rev Drug Discov 2010; 9:215-236.Kadono K., Akabane T., Tabata K., et al. Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor. // Drug Metab Dispos 2010; 38:1230-1237.Kadono K., Akabane T., Tabata K., et al. Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor. // Drug Metab Dispos 2010; 38:1230-1237.Krecic-Shepard M.E., Barnas C.R., Slimko J., et al. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. // J Clin Pharmacol 2000; 40:219-230.Krecic-Shepard M.E., Barnas C.R., Slimko J., et al. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. // J Clin Pharmacol 2000; 40:219-230.Kennedy M. Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence. // Clin Pharmacol Ther 2008; 84:662-673.Kennedy M. Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence. // Clin Pharmacol Ther 2008; 84:662-673.Marzolini C., Paus E., Buclin T., Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. // Clin Pharmacol Ther 2004; 75:13-33.Marzolini C., Paus E., Buclin T., Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. // Clin Pharmacol Ther 2004; 75:13-33.Ofotokun I. Sex differences in the pharmacologic effects of antiretroviral drugs: potential roles of drug transporters and phase 1 and 2 metabolizing enzymes. // Top HIV Med 2005; 13:79-83.Ofotokun I. Sex differences in the pharmacologic effects of antiretroviral drugs: potential roles of drug transporters and phase 1 and 2 metabolizing enzymes. // Top HIV Med 2005; 13:79-83.Buchanan F.F., Myles P.S., Cicuttini F. Patient sex and its influence on general anaesthesia. // Anaesth Intensive Care 2009; 37:207-218.Buchanan F.F., Myles P.S., Cicuttini F. Patient sex and its influence on general anaesthesia. // Anaesth Intensive Care 2009; 37:207-218.Frohlich M., Albermann N., Sauer A., et al. In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. // Biochem Pharmacol 2004; 68:2409-2416.Frohlich M., Albermann N., Sauer A., et al. In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. // Biochem Pharmacol 2004; 68:2409-2416.Rathore S.S., Wang Y., Krumholz H.M. Sex-based differences in the effect of digoxin for the treatment of heart failure. // N Engl J Med 2002; 347:1403-1411.Rathore S.S., Wang Y., Krumholz H.M. Sex-based differences in the effect of digoxin for the treatment of heart failure. // N Engl J Med 2002; 347:1403-1411.Rodenburg E.M., Stricker B.H., Visser L.E. Sex differences in cardiovascular drug-induced adverse reactions causing hospital admissions. // Br J Clin Pharmacol 2012; 74:1045-1052.Rodenburg E.M., Stricker B.H., Visser L.E. Sex differences in cardiovascular drug-induced adverse reactions causing hospital admissions. // Br J Clin Pharmacol 2012; 74:1045-1052.Adams K.F. Jr., Patterson J.H., Gattis W.A., et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. // J Am Coll Cardiol 2005; 46:497-504.Adams K.F. Jr., Patterson J.H., Gattis W.A., et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. // J Am Coll Cardiol 2005; 46:497-504.Rubinow D.R., Moore M. Sex-dependent modulation of treatment response. // Dialogues Clin Neurosci 2004; 6:39-51.Rubinow D.R., Moore M. Sex-dependent modulation of treatment response. // Dialogues Clin Neurosci 2004; 6:39-51.Pleym H., Spigset O., Kharasch E.D., et al. Gender differences in drug effects: implications for anesthesiologists. // Acta Anaesthesiol Scand 2003; 47:241-259.Pleym H., Spigset O., Kharasch E.D., et al. Gender differences in drug effects: implications for anesthesiologists. // Acta Anaesthesiol Scand 2003; 47:241-259.Beierle I., Meibohm B., Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. // Int J Clin Pharmacol Ther 1999; 37:529-547.Beierle I., Meibohm B., Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. // Int J Clin Pharmacol Ther 1999; 37:529-547.Waxman D.J., Holloway M.G. Sex differences in the expression of hepatic drug metabolizing enzymes. // Mol Pharmacol 2009; 76:215-228.Waxman D.J., Holloway M.G. Sex differences in the expression of hepatic drug metabolizing enzymes. // Mol Pharmacol 2009; 76:215-228.Lewis D.F. 57 varieties: the human cytochromes P450. // Pharmacogenomics 2004; 5:305-318.Lewis D.F. 57 varieties: the human cytochromes P450. // Pharmacogenomics 2004; 5:305-318.Zamek-Gliszczynski M.J., Hoffmaster K.A., Nezasa K., et al. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. // Eur J Pharm Sci 2006; 27:447-486.Zamek-Gliszczynski M.J., Hoffmaster K.A., Nezasa K., et al. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. // Eur J Pharm Sci 2006; 27:447-486.Zanger U.M., Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. // Pharmacol Ther 2013; 138:103-141.Zanger U.M., Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. // Pharmacol Ther 2013; 138:103-141.Nebert D.W., Wikvall K., Miller W.L. Human cytochromes P450 in health and disease. // Philos Trans R Soc Lond B Biol Sci 2013; 368:20120431.Nebert D.W., Wikvall K., Miller W.L. Human cytochromes P450 in health and disease. // Philos Trans R Soc Lond B Biol Sci 2013; 368:20120431.Franconi F., Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. // Br J Pharmacol 2014; 171:580-594.Franconi F., Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. // Br J Pharmacol 2014; 171:580-594.Tracy T.S., Venkataramanan R., Glover D.D., Caritis S.N. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. // Am J Obstet Gynecol 2005; 192:633-639.Tracy T.S., Venkataramanan R., Glover D.D., Caritis S.N. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. // Am J Obstet Gynecol 2005; 192:633-639.Lamba V., Lamba J., Yasuda K., et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. // J Pharmacol Exp Ther 2003; 307:906-922.Lamba V., Lamba J., Yasuda K., et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. // J Pharmacol Exp Ther 2003; 307:906-922.Higashi E., Fukami T., Itoh M., et al. Human CYP2A6 is induced by estrogen via estrogen receptor. // Drug Metab Dispos 2007; 35:1935-1941.Higashi E., Fukami T., Itoh M., et al. Human CYP2A6 is induced by estrogen via estrogen receptor. // Drug Metab Dispos 2007; 35:1935-1941.McGready R., Stepniewska K., Seaton E., et al. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. // Eur J Clin Pharmacol 2003; 59:553-557.McGready R., Stepniewska K., Seaton E., et al. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. // Eur J Clin Pharmacol 2003; 59:553-557.Wadelius M., Darj E., Frenne G., Rane A. Induction of CYP2D6 in pregnancy. // Clin Pharmacol Ther 1997; 62:400-407.Wadelius M., Darj E., Frenne G., Rane A. Induction of CYP2D6 in pregnancy. // Clin Pharmacol Ther 1997; 62:400-407.Sinues B., Fanlo A., Mayayo E., et al. CYP2A6 activity in a healthy Spanish population: effect of age, sex, smoking, and oral contraceptives. // Hum Exp Toxicol 2008; 27:367-372.Sinues B., Fanlo A., Mayayo E., et al. CYP2A6 activity in a healthy Spanish population: effect of age, sex, smoking, and oral contraceptives. // Hum Exp Toxicol 2008; 27:367-372.Zaigler M., Rietbrock S., Szymanski J., et al. Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women. // Int J Clin Pharmacol Ther 2000; 38:235-244.Zaigler M., Rietbrock S., Szymanski J., et al. Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women. // Int J Clin Pharmacol Ther 2000; 38:235-244.Cubała W.J., Wiglusz M., Burkiewicz A., et al. Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor. // Eur J Clin Pharmacol 2010; 66:955.Cubała W.J., Wiglusz M., Burkiewicz A., et al. Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor. // Eur J Clin Pharmacol 2010; 66:955.Greenblatt D.J., von Moltke L.L. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. // J Clin Pharmacol 2008; 48:1350-1355.Greenblatt D.J., von Moltke L.L. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. // J Clin Pharmacol 2008; 48:1350-1355.Hu Z.Y., Zhao Y.S. Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis. // Drug Metab Dispos 2010; 38:817-823.Hu Z.Y., Zhao Y.S. Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis. // Drug Metab Dispos 2010; 38:817-823.Chetty M., Mattison D., Rostami-Hodjegan A. Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus. // Curr Drug Metab 2012; 13:778-786.Chetty M., Mattison D., Rostami-Hodjegan A. Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus. // Curr Drug Metab 2012; 13:778-786.Aminimanizani A., Beringer P., Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. // Clin Pharmacokinet 2001; 40:169-187.Aminimanizani A., Beringer P., Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. // Clin Pharmacokinet 2001; 40:169-187.Overholser B.R., Kays M.B., Forrest A., Sowinski K.M. Sex-related differences in the pharmacokinetics of oral ciprofloxacin. // J Clin Pharmacol 2004; 44:1012-1022.Overholser B.R., Kays M.B., Forrest A., Sowinski K.M. Sex-related differences in the pharmacokinetics of oral ciprofloxacin. // J Clin Pharmacol 2004; 44:1012-1022.Zhang X., Overholser B.R., Kays M.B., et al. Gatifloxacin pharmacokinetics in healthy men and women. // J Clin Pharmacol 2006; 46:1154-1162.Zhang X., Overholser B.R., Kays M.B., et al. Gatifloxacin pharmacokinetics in healthy men and women. // J Clin Pharmacol 2006; 46:1154-1162.Mackenzie P.I., Bock K.W., Burchell B., et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. // Pharmacogenet Genomics 2005; 15:677-685.Mackenzie P.I., Bock K.W., Burchell B., et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. // Pharmacogenet Genomics 2005; 15:677-685.Hu D.G., Mackenzie P.I. Estrogen receptor alpha, fos-related antigen-2, and c-Jun coordinately regulate human UDP glucuronosyltransferase 2B15 and 2B17 expression in response to 17beta-estradiol in MCF-7 cells. // Mol Pharmacol 2009; 76:425-439.Hu D.G., Mackenzie P.I. Estrogen receptor alpha, fos-related antigen-2, and c-Jun coordinately regulate human UDP glucuronosyltransferase 2B15 and 2B17 expression in response to 17beta-estradiol in MCF-7 cells. // Mol Pharmacol 2009; 76:425-439.Court M.H., Hao Q., Krishnaswamy S., et al. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. // J Pharmacol Exp Ther 2004; 310: 656-665.Court M.H., Hao Q., Krishnaswamy S., et al. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. // J Pharmacol Exp Ther 2004; 310: 656-665.Abernethy D.R., Divoll M., Greenblatt D.J., Ameer B. Obesity, sex, and acetaminophen disposition. // Clin Pharmacol Ther 1982; 31:783-790.Abernethy D.R., Divoll M., Greenblatt D.J., Ameer B. Obesity, sex, and acetaminophen disposition. // Clin Pharmacol Ther 1982; 31:783-790.

The authors declare that there are no conflicts of interest present.